Ionis Pharmaceuticals Inc (IONS) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Ionis Pharmaceuticals Inc

NASDAQ | IONS

28.52

USD

-0.19 (-0.66%)

AT CLOSE (AS OF Apr 3, 2025)

$4.6B

MARKET CAP

P/E Ratio

-3.04

EPS

$52

52 Week High

$27

52 Week Low

LIFE SCIENCES

Sector

IONS Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

IONS Technicals

Tags:

IONS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$411M
Total Revenue	$695M
Cost Of Revenue	$284M
Costof Goods And Services Sold	$11M
Operating Income	-$475M
Selling General And Administrative	$267M
Research And Development	$902M
Operating Expenses	$273M
Investment Income Net	$107M
Net Interest Income	-$90M
Interest Income	-
Interest Expense	$17M
Non Interest Income	$698M
Other Non Operating Income	$1.3M
Depreciation	$9.6M
Depreciation And Amortization	$2.3M
Income Before Tax	-$460M
Income Tax Expense	-$6.2M
Interest And Debt Expense	$6.7M
Net Income From Continuing Operations	-$454M
Comprehensive Income Net Of Tax	-$452M
Ebit	-$443M
Ebitda	-$441M
Net Income	-$454M

Revenue & Profitability

Earnings Performance

IONS Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$3B
Total Current Assets	$2.6B
Cash And Cash Equivalents At Carrying Value	$242M
Cash And Short Term Investments	$2.3B
Inventory	$13M
Current Net Receivables	-
Total Non Current Assets	$1B
Property Plant Equipment	$94M
Accumulated Depreciation Amortization Ppe	$106M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$2.1B
Long Term Investments	$653M
Short Term Investments	$2.1B
Other Current Assets	$218M
Other Non Current Assets	$127M
Total Liabilities	$2.4B
Total Current Liabilities	$309M
Current Accounts Payable	$43M
Deferred Revenue	$235M
Current Debt	$165K
Short Term Debt	-
Total Non Current Liabilities	$1.5B
Capital Lease Obligations	$162M
Long Term Debt	$1.3B
Current Long Term Debt	$165K
Long Term Debt Noncurrent	$1.2B
Short Long Term Debt Total	$1.3B
Other Current Liabilities	$9.3M
Other Non Current Liabilities	$542M
Total Shareholder Equity	$600M
Treasury Stock	-
Retained Earnings	-$2.2B
Common Stock	$158K
Common Stock Shares Outstanding	$158M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$501M
Payments For Operating Activities	$31M
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$182M
Change In Operating Assets	$25M
Depreciation Depletion And Amortization	-$19M
Capital Expenditures	$50M
Change In Receivables	-
Change In Inventory	$5.1M
Profit Loss	-$454M
Cashflow From Investment	-$134M
Cashflow From Financing	$478M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$489M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$523M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$454M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$411M
Total Revenue	$695M
Cost Of Revenue	$284M
Costof Goods And Services Sold	$11M
Operating Income	-$475M
Selling General And Administrative	$267M
Research And Development	$902M
Operating Expenses	$273M
Investment Income Net	$107M
Net Interest Income	-$90M
Interest Income	-
Interest Expense	$17M
Non Interest Income	$698M
Other Non Operating Income	$1.3M
Depreciation	$9.6M
Depreciation And Amortization	$2.3M
Income Before Tax	-$460M
Income Tax Expense	-$6.2M
Interest And Debt Expense	$6.7M
Net Income From Continuing Operations	-$454M
Comprehensive Income Net Of Tax	-$452M
Ebit	-$443M
Ebitda	-$441M
Net Income	-$454M

Dividends

Field	Value
Ex Dividend Date	2000-05-10
Declaration Date	None
Record Date	None
Payment Date	None
Amount	0.186

IONS Profile

Ionis Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	9.42%	-	776,312,724
NVDA	$101.80	-7.81%	$2.68T	338,769,412
INTC	$22.43	2.05%	$95.85B	242,972,129
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	211,931,403

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$159.81	2.86%	$399.65B	13,235,689
PG	$172.39	1.71%	$399.61B	9,393,270
ABBV	$201.64	-1.73%	$364.89B	7,580,327
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$73.92	2.35%	$225.70B	7,926,952

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$5.99	1,796.17%	$744.62K	310,904
MRM	$0.69	87.76%	$2.91M	54,062,078
PTIX	$0.42	84.14%	$4.04M	177,332,811
OSRH	$2.47	68.03%	$40.06M	89,499,750
OMQS	$0.06	62.16%	$1.50M	59,659

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,941,899
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
ICCT	$2.07	-56.14%	$9.78M	12,637,345